glp-1 rheumatoid arthritis study Glucagon-like Peptide-1 Receptor Agonists in Arthritis: A Scoping Review of Metabolic, Anti-Inflammatory, and Cardioprotective Effects GLP-1 Medications & Rheumatoid Arthritis:

In the Lira Pump study, they decreased basal insulin by 10%, but increased bolus by 15% ( Our current practice is to consider a ~20% bolus insulin decrease and a ~10% basal insulin decrease before GLP-1RA initiation, although prior A1c, risk of hypoglycemia, potential risk of ketosis due to reduced insulin doses, as well as other patient-specific factors should guide the final insulin dose changes

According to a qualitative study of online discussion forums, users frequently report these effects and attempt to mitigate them through dose adjustments, antiemetics, or timing changes all without medical guidance

The changes appear natural, not sudden, because they come from deep repair rather than surface-level lightening

From $49 for the first month with a 5-month plan

10.1016/j.neuron.2017.07.010 Neuron 28 KangX.WangD.ZhangL.HuangT.LiuS.FengX.et al (2023)